Interleukin-23 Inhibitors
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis pati...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-04-01
|
| Series: | Turkderm Turkish Archives of Dermatology and Venereology |
| Subjects: | |
| Online Access: | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-06337&look4= |
| Summary: | For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis patients being treated with IL-23 inhibitors. In patients with partial response, dose increase may be planned, or topical corticosteroids, vitamin D analogs, methotrexate, or phototherapy (UVB) may be added to the treatment. |
|---|---|
| ISSN: | 2651-5164 |